Barclays
RPRX icon

Barclays’s Royalty Pharma RPRX Stock Holding History

Barclays’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$20.8M Sell
356,020
-266,413
-43% -$15.7M ﹤0.01% 1228
2026
Q2 		$34.9M Sell
622,433
-96,182
-13% -$5.01M 0.01% 878
2026
Q1 		$34.5M Buy
718,615
+176,551
+33% +$7.73M 0.01% 867
2025
Q4 		$20.9M Sell
542,064
-10,495
-2% -$400K 0.01% 1234
2025
Q3 		$19.5M Buy
552,559
+213,197
+63% +$7.72M ﹤0.01% 1245
2025
Q2 		$12.2M Sell
339,362
-27,868
-8% -$923K ﹤0.01% 1430
2025
Q1 		$11.4M Buy
367,230
+3,922
+1% +$124K ﹤0.01% 1313
2024
Q4 		$9.27M Buy
363,308
+54,421
+18% +$1.44M ﹤0.01% 1630
2024
Q3 		$8.74M Buy
308,887
+43,339
+16% +$1.2M ﹤0.01% 1577
2024
Q2 		$7M Sell
265,548
-19,341
-7% -$536K ﹤0.01% 1347
2024
Q1 		$8.65M Sell
284,889
-117,229
-29% -$3.46M ﹤0.01% 1496
2023
Q4 		$11.3M Sell
402,118
-911,961
-69% -$25.1M ﹤0.01% 1433
2023
Q3 		$35.7M Buy
1,314,079
+210,414
+19% +$6.25M 0.02% 590
2023
Q2 		$33.9M Buy
1,103,665
+670,204
+155% +$22.7M 0.02% 572
2023
Q1 		$15.6M Buy
433,461
+31,271
+8% +$1.16M 0.01% 962
2022
Q4 		$15.9M Buy
402,190
+181,497
+82% +$7.58M 0.01% 996
2022
Q3 		$8.87M Buy
220,693
+9,914
+5% +$423K 0.01% 903
2022
Q2 		$8.86M Buy
210,779
+25,219
+14% +$1.03M 0.01% 1064
2022
Q1 		$7.23M Buy
+185,560
New +$7.29M 0.01% 1053

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Barclays's RPRX Position: Q3 2026 in Review

Barclays reduced its Royalty Pharma (RPRX) stake by 43% in Q3 2026, selling an estimated $15.7M and leaving 356,020 shares worth $20.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1228.

Barclays first reported a position in RPRX in Q1 2022 and has held it in 19 quarters since. The position peaked at $35.7M in Q3 2023. 573 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Barclays held 356,020 shares of Royalty Pharma worth $20.8M as of Q3 2026.
  • Barclays sold 266,413 Royalty Pharma shares in Q3 2026, an estimated $15.7M.
  • Royalty Pharma made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1228 holding.
  • Barclays first reported a position in Royalty Pharma in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Royalty Pharma position peaked at $35.7M in Q3 2023.
  • 573 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.